1 patient enrolled, of a total of 80. And I do not think Pancreatic cancer is that common (luckily)
It's just the beginning of the study, so it could prove that Oncosil's treatment does work... or not!
From there, if it works, there's the long road to approval.
All this in a high interest rates climate.
My confidence as investor in OSL shattered by dirt-cheap valuation on the capital rise. I would sell if I could recoup most of my initial investment, but these guys ensured there's no easy way out.
I cannot see this recovering in 2-3 years, if ever
Ann: First patient enrolled in the TRIPP-FFX Clinical Study, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.015(1.28%) |
Mkt cap ! $22.30M | |||
| Open | High | Low | Value | Volume |
| $1.17 | $1.21 | $1.17 | $19.35K | 16.24K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2902 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.20 | 25000 | 1 |
View Market Depth
| Last trade - 15.46pm 22/07/2025 (20 minute delay) ? |
| OSL (ASX) Chart |